Skip to content
Screener

Rapport Therapeutics, Inc. RAPP Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$20.0MBeat by $12.5M
EPS-$0.42Beat by $0.14
Revenue estimate$7.5M
EPS estimate-$0.56

Next report

Nov 5, 2026 (in 3 months)
EPS estimate-$1.21

Financials

Q1 2026

Income statement

See full
Revenue$20.0M—
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.5B+309%
Enterprise value$1.43B+352%

Returns & leverage

See full
Return on equity-28.3%—
Debt / equity0×0.0×
Current ratio27.1×-3.9×

Versus estimates

Revenue

Q1 2026$20.0MBeat by $12.5M

Diluted EPS

Q2 2026-$1.19Miss by $0.07
Q1 2026-$0.42Beat by $0.14
Q4 2025-$0.72Miss by $0.07Q3 2025-$0.71Beat by $0.06Q2 2025-$0.75Beat by $0.12Q1 2025-$0.68Beat by $0.09

FAQ

When did Rapport Therapeutics, Inc. report Q1 2026 earnings?
Rapport Therapeutics, Inc. (RAPP) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Rapport Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Rapport Therapeutics, Inc. reported revenue of $20.0M and eps of $-0.42 for Q1 2026.
Did Rapport Therapeutics, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $7.5M by $12.5M. EPS beat the consensus estimate of $-0.56 by $0.14.
How did Rapport Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 38.2% from $-0.68.
Where can I find Rapport Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-210324) and the 10-Q periodic report (0001193125-26-210355) directly on SEC EDGAR. The filing index links above go to sec.gov.